Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation

Cancer Immunology, Immunotherapy

Volumn 66, Issue 1, 2017, Pages

  Ellmark, Peter ^a,b   Mangsbo, Sara M ^c   Furebring, Christina ^a   Norlén, Per ^a   Tötterman, Thomas H ^c  

^a Alligator Bioscience AB   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Bispecific antibody; Cancer; Immuno oncology; Immunotherapy; Intratumoral; Tumor directed immunotherapy

Indexed keywords

BISPECIFIC ANTIBODY; CD3 TARGETING BISPECIFIC ANTIBODY; IMMUNOCYTOKINE; IMMUNOMODULATING AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR;

CANCER IMMUNOTHERAPY; CLINICAL STUDY; DRUG DESIGN; HUMAN; INTRATUMORAL DRUG ADMINISTRATION; NONHUMAN; PRECLINICAL STUDY; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR MICROENVIRONMENT; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES;

ANTIBODIES, BISPECIFIC; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES;

EID: 84990818472     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-016-1909-3     Document Type: Review

References (49)

1. Ascierto PA (2015) Immunotherapies and novel combinations: the focus of advances in the treatment of melanoma. Cancer Immunol Immunother 64:271–274. doi:10.1007/s00262-014-1647-3
2. Hammerich L, Binder A, Brody JD (2015) In situ vaccination: cancer immunotherapy both personalized and off-the-shelf. Mol Oncol 9:1966–1981. doi:10.1016/j.molonc.2015.10.016
3. Pierce RH, Campbell JS, Pai SI, Brody JD, Kohrt HE (2015) In-situ tumor vaccination: bringing the fight to the tumor. Hum Vaccin Immunother 11:1901–1909. doi:10.1080/21645515.2015.1049779
4. Wong KK, Li WA, Mooney DJ, Dranoff G (2016) Advances in therapeutic cancer vaccines. Adv Immunol 130:191–249. doi:10.1016/bs.ai.2015.12.001
5. Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD, Peggs KS, Ravetch JV, Allison JP, Quezada SA (2013) Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 210:1695–1710. doi:10.1084/jem.20130579
6. Romano E, Kusio-Kobialka M, Foukas PG, Baumgaertner P, Meyer C, Ballabeni P, Michielin O, Weide B, Romero P, Speiser DE (2015) Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci 112:6140–6145. doi:10.1073/pnas.1417320112
7. Sharma P, Allison JP (2015) Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161:205–214. doi:10.1016/j.cell.2015.03.030
8. Sanmamed MF, Pastor F, Rodriguez A, Perez-Gracia JL, Rodriguez-Ruiz ME, Jure-Kunkel M, Melero I (2015) Agonists of co-stimulation in cancer immunotherapy directed against CD137, OX40, GITR, CD27, CD28, and ICOS. Semin Oncol 42:640–655. doi:10.1053/j.seminoncol.2015.05.014
9. Ellmark P, Mangsbo SM, Furebring C, Tötterman TH, Norlén P (2015) Kick-starting the cancer-immunity cycle by targeting CD40. Oncoimmunology 4:e1011484-1-3. doi:10.1080/2162402X.2015.1011484
10. Vonderheide RH, Glennie MJ (2013) Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res 19:1035–1043. doi:10.1158/1078-0432.CCR-12-2064
11. Sandin LC, Orlova A, Gustafsson E, Ellmark P, Tolmachev V, Tötterman TH, Mangsbo SM (2014) Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer. Cancer Immunol Res 2:80–90. doi:10.1158/2326-6066.CIR-13-0067
12. − tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci 99:5561–5566. doi:10.1073/pnas.082107699
13. Fransen MF, Sluijter M, Morreau H, Arens R, Melief CJ (2011) Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin Cancer Res 17:2270–2280. doi:10.1158/1078-0432.CCR-10-2888
14. Jackaman C, Lew AM, Zhan Y, Allan JE, Koloska B, Graham PT, Robinson BW, Nelson DJ (2008) Deliberately provoking local inflammation drives tumors to become their own protective vaccine site. Int Immunol 20:1467–1479. doi:10.1093/intimm/dxn104
15. Mangsbo SM, Broos S, Fletcher E, Veitonmäki N, Furebring C, Dahlén E, Norlén P, Lindstedt M, Tötterman TH, Ellmark P (2015) The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity. Clin Cancer Res 21:1115–1126. doi:10.1158/1078-0432.CCR-14-0913
16. Lindqvist C, Sandin LC, Fransson M, Loskog A (2009) Local AdCD40L gene therapy is effective for disseminated murine experimental cancer by breaking T-cell tolerance and inducing tumor cell growth inhibition. J Immunother 32:785–792. doi:10.1097/CJI.0b013e3181acea69
17. Loskog A, Björkland A, Brown MP, Korsgren O, Malmström PU, Tötterman TH (2001) Potent antitumor effects of CD154 transduced tumor cells in experimental bladder cancer. J Urol 166:1093–1097. doi:10.1016/S0022-5347(05)65928-9
18. Tuve S, Chen BM, Liu Y, Cheng TL, Touré P, Sow PS, Feng Q, Kiviat N, Strauss R, Ni S, Li ZY, Roffler SR (2007) Lieber A (2007) Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. Cancer Res 67:5929–5939. doi:10.1158/0008-5472.CAN-06-4296
19. + T-cell-dependent tumor eradication and decreases risk of toxic side effects. Clin Cancer Res 19:5381–5389. doi:10.1158/1078-0432.CCR-12-0781
20. Sandin LC, Eriksson F, Ellmark P, Loskog AS, Tötterman TH, Mangsbo SM (2014) Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo. Oncoimmunology 3:e27614-1-8. doi:10.4161/onci.27614
21. Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A, Massard C, Fuerea A, Ribrag V, Gazzah A, Armand JP, Amellal N, Angevin E, Noel N, Boutros C, Mateus C, Robert C, Soria JC, Marabelle A, Lambotte O (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139–148. doi:10.1016/j.ejca.2015.11.016
22. Marabelle A, Kohrt H, Sagiv-Barfi I, Ajami B, Axtell RC, Zhou G, Rajapaksa R, Green MR, Torchia J, Brody J, Luong R, Rosenblum MD, Steinman L, Levitsky HI, Tse V, Levy R (2013) Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest 123:2447–2463. doi:10.1172/JCI64859
23. Palazón A, Martínez-Forero I, Teijeira A, Morales-Kastresana A, Alfaro C, Sanmamed MF, Perez-Gracia JL, Peñuelas I, Hervás-Stubbs S, Rouzaut A, de Landázuri MO, Jure-Kunkel M, Aragonés J, Melero I (2012) The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy. Cancer Discov 2:608–623. doi:10.1158/2159-8290.CD-11-0314
24. Kim YH, Gratzinger D, Harrison C, Brody JD, Czerwinski DK, Ai WZ, Morales A, Abdulla F, Xing L, Navi D, Tibshirani RJ, Advani RH, Lingala B, Shah S, Hoppe RT, Levy R (2012) In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. Blood 119:355–363. doi:10.1182/blood-2011-05-355222
25. + T cells that are effective in adoptive therapy for large and established tumors. Blood 117:118–127. doi:10.1182/blood-2010-06-288456
26. Malmström PU, Loskog AS, Lindqvist CA, Mangsbo SM, Fransson M, Wanders A, Gårdmark T, Tötterman TH (2010) AdCD40L immunogene therapy for bladder carcinoma—the first phase I/IIa trial. Clin Cancer Res 16:3279–3287. doi:10.1158/1078-0432.CCR-10-0385
27. von Euler H, Sadeghi A, Carlsson B, Rivera P, Loskog A, Segall T, Korsgren O, Tötterman TH (2008) Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma. J Immunother 31:377–384. doi:10.1097/CJI.0b013e31816a812d
28. Westberg S, Sadeghi A, Svensson E, Segall T, Dimopoulou M, Korsgren O, Hemminki A, Loskog AS, Tötterman TH, von Euler H (2013) Treatment efficacy and immune stimulation by AdCD40L gene therapy of spontaneous canine malignant melanoma. J Immunother 36:350–358. doi:10.1097/CJI.0b013e31829d8a1b
29. Loskog A, Maleka A, Mangsbo S, Svensson E, Lundberg C, Nilsson A, Krause J, Agnarsdóttir M, Sundin A, Ahlström H, Tötterman TH, Ullenhag G (2016) Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients. Br J Cancer 114:872–880. doi:10.1038/bjc.2016.42
30. Hemminki A (2014) Oncolytic immunotherapy: where are we clinically? Scientifica (Cairo) 2014:862925. doi:10.1155/2014/862925
31. Broos S, Sandin LC, Apel J, Tötterman TH, Akagi T, Akashi M, Borrebaeck CA, Ellmark P, Lindstedt M (2012) Synergistic augmentation of CD40-mediated activation of antigen-presenting cells by amphiphilic poly(γ-glutamic acid) nanoparticles. Biomaterials 33:6230–6239. doi:10.1016/j.biomaterials.2012.05.011
32. Fransen MF, Cordfunke RA, Sluijter M, van Steenbergen MJ, Drijfhout JW, Ossendorp F, Hennink WE, Melief CJ (2014) Effectiveness of slow-release systems in CD40 agonistic antibody immunotherapy of cancer. Vaccine 32:1654–1660. doi:10.1016/j.vaccine.2014.01.056
33. McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, Watkins TB, Shafi S, Murugaesu N, Mitter R, Akarca AU, Linares J, Marafioti T, Henry JY, Van Allen EM, Miao D, Schilling B, Schadendorf D, Garraway LA, Makarov V, Rizvi NA, Snyder A, Hellmann MD, Merghoub T, Wolchok JD, Shukla SA, Wu CJ, Peggs KS, Chan TA, Hadrup SR, Quezada SA, Swanton C (2016) Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351:1463–1469. doi:10.1126/science.aaf1490
34. Kiefer JD, Neri D (2016) Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor site. Immunol Rev 270:178–192. doi:10.1111/imr.12391
35. Neri D, Sondel PM (2016) Immunocytokines for cancer treatment: past, present and future. Curr Opin Immunol 40:96–102. doi:10.1016/j.coi.2016.03.006
36. Sondel PM, Gillies SD (2012) Current and potential uses of immunocytokines as cancer immunotherapy. Antibodies 1:149–171. doi:10.3390/antib1020149
37. Danielli R, Patuzzo R, Ruffini PA, Maurichi A, Giovannoni L, Elia G, Neri D, Santinami M (2015) Armed antibodies for cancer treatment: a promising tool in a changing era. Cancer Immunol Immunother 64:113–121. doi:10.1007/s00262-014-1621-0
38. Yoshida GJ (2015) Metabolic reprogramming: the emerging concept and associated therapeutic strategies. J Exp Clin Cancer Res 34:1–10. doi:10.1186/s13046-015-0221-y
39. Vaughn DE, Bjorkman PJ (1998) Structural basis of pH-dependent antibody binding by the neonatal Fc receptor. Structure 6:63–73
40. Polu KR, Lowman HB (2014) Probody therapeutics for targeting antibodies to diseased tissue. Expert Opin Biol Ther 14:1049–1053. doi:10.1517/14712598.2014.920814
41. Sanford M (2015) Blinatumomab: first global approval. Drugs 75:321–327. doi:10.1007/s40265-015-0356-3
42. Zhukovsky EA, Morse RJ, Maus MV (2016) Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection. Curr Opin Immunol 40:24–35. doi:10.1016/j.coi.2016.02.006
43. Wilson NS, Yang B, Yang A, Loeser S, Marsters S, Lawrence D, Li Y, Pitti R, Totpal K, Yee S, Ross S, Vernes JM, Lu Y, Adams C, Offringa R, Kelley B, Hymowitz S, Daniel D, Meng G, Ashkenazi A (2011) An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell 19:101–113. doi:10.1016/j.ccr.2010.11.012
44. Li F, Ravetch JV (2013) Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivo. Proc Natl Acad Sci 110:19501–19506. doi:10.1073/pnas.1319502110
45. White AL, Chan HT, Roghanian A, French RR, Mockridge CI, Tutt AL, Dixon SV, Ajona D, Verbeek JS, Al-Shamkhani A, Cragg MS, Beers SA, Glennie MJ (2011) Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J Immunol 187:1754–1763. doi:10.4049/jimmunol.1101135
46. French RR, Chan HT, Tutt AL, Glennie MJ (1999) CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med 5:548–553. doi:10.1038/8426
47. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellström KE, Mittler RS, Chen L (1997) Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 3:682–685
48. Müller D, Frey K, Kontermann RE (2008) A novel antibody-4-1BBL fusion protein for targeted costimulation in cancer immunotherapy. J Immunother 31:714–722. doi:10.1097/CJI.0b013e31818353e9
49. Hornig N, Kermer V, Frey K, Diebolder P, Kontermann RE, Müller D (2012) Combination of a bispecific antibody and costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy. J Immunother 35:418–429. doi:10.1097/CJI.0b013e3182594387